+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain



Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain



Oncotarget 8(1): 1234-1246



Polo-like kinase 1 (Plk1) is a promising target for cancer therapy due to its essential role in cell division. In addition to a highly conserved kinase domain, Plk1 also contains a Polo-Box domain (PBD), which is essential for Plk1's subcellular localization and mitotic functions. We adopted a fluorescence polarization assay and identified a new Plk1 PBD inhibitor T521 from a small-molecule compound library. T521 specifically inhibits the PBD of Plk1, but not those of Plk2-3. T521 exhibits covalent binding to some lysine residues of Plk1 PBD, which causes significant changes in the secondary structure of Plk1 PBD. Using a cell-based assay, we showed that T521 impedes the interaction between Plk1 and Bub1, a mitotic checkpoint protein. Moreover, HeLa cells treated with T521 exhibited dramatic mitotic defects. Importantly, T521 suppresses the growth of A549 cells in xenograft nude mice. Taken together, we have identified a novel Plk1 inhibitor that specifically disrupts the functions of Plk1 PBD and shows anticancer activity.

(PDF emailed within 1 workday: $29.90)

Accession: 058038102

Download citation: RISBibTeXText

PMID: 27902479


Related references

Structural insights into the inhibitor binding and new inhibitor design to Polo-like kinase-1 Polo-box domain using computational studies. Journal of Biomolecular Structure and Dynamics 2018: 1-12, 2018

Selective Degradation of Polo-like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Polo-Box Domain. Angewandte Chemie 2018, 2018

A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening. Journal of Advanced Research 16: 145-156, 2019

Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1. Amino Acids 46(11): 2595-2603, 2015

DITMD-induced mitotic defects and apoptosis in tumor cells by blocking the polo-box domain-dependent functions of polo-like kinase 1. European Journal of Pharmacology 2019, 2019

Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1. Plos One 9(9): E107432, 2015

Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1. Bioorganic Chemistry 81: 278-288, 2018

Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1. Bioorganic and Medicinal Chemistry 25(24): 6581-6588, 2017

Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds. Investigational New Drugs 2019, 2019

Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1. Chemmedchem 10(1): 158-163, 2015

Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. Acs Chemical Biology 7(5): 805-810, 2012

The Polo-box domain: a molecular integrator of mitotic kinase cascades and Polo-like kinase function. Cell Cycle 3(2): 128-131, 2004

In vivo tumor imaging using polo-box domain of polo-like kinase 1 targeted peptide. Biomaterials 33(29): 6915-6925, 2012

Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain. Chembiochem 17(8): 759-767, 2017

Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1. Bioorganic and Medicinal Chemistry 21(9): 2623-2634, 2013